{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:42:21Z","timestamp":1791477741378,"version":"4.3.4"},"reference-count":68,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,8,31]],"date-time":"2022-08-31T00:00:00Z","timestamp":1661904000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> The effect of herbal medicine (HM) on amyotrophic lateral sclerosis (ALS) is controversial. Clinical trials investigating HMs continue; however, the use of HM is still questioned. We aimed to systematically review the literature pertaining to the effects and safety of HM in ALS.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> Randomised controlled trials (RCTs) that investigated the efficacy of HMs in ALS patients compared to any types of controls were identified. Nine databases and six registers were searched from their inception dates to 25 March 2022. Per the PRISMA guidelines, trials were identified and extracted. The risk of bias was evaluated using the Cochrane\u2019s tool. Certainty of evidence was assessed as per the GRADE criteria. Forest plots were constructed to assess the effect size and corresponding 95% CIs using fixed-effect models, and random-effect models were employed when required. The primary outcome was the activity limitation measured by validated tools, such as the revised ALS Functional Rating Scale.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> Twenty studies (<jats:italic>N<\/jats:italic> = 1,218) were eligible. Of these, only five studies were double-blinded, and two were placebo-controlled. Fourteen HMs (fifty-one single botanicals) were involved; <jats:italic>Astragalus mongholicus Bunge, Atractylodes macrocephala Koidz.,<\/jats:italic> and <jats:italic>Glycyrrhiza glabra L.<\/jats:italic> were commonly used in nine, eight, and six trials, respectively. For delaying activity limitation, <jats:italic>Jiweiling<\/jats:italic> injection (MD, 2.84; 95% CI, 1.21 to 4.46; <jats:italic>p<\/jats:italic> = 0.0006) and <jats:italic>Shenmai<\/jats:italic> injection (SMD, 1.07; 0.69 to 1.45; <jats:italic>p<\/jats:italic> &amp;lt; 0.00001) were significantly more efficacious than Riluzole, but the evidence was low quality. For ameliorating motor neuron loss, <jats:italic>Jiweiling<\/jats:italic> injection [right abductor pollicis brevis (APB): MD, 32.42; 7.91 to 56.93; <jats:italic>p<\/jats:italic> = 0.01 and left APB: MD, 34.44; 12.85 to 56.03; <jats:italic>p<\/jats:italic> = 0.002] was favoured, but the evidence was very low quality. Nine studies reported one hundred and twenty-three adverse events, twenty-six of which occurred in the treatment groups and ninety-seven in the control groups.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> Very low to low quality of evidence suggests that HMs seem to produce superior treatment responses for ALS without increased risk of adverse events. Additional studies with homogeneous participants, reduced methodological issues, and more efficient outcome measures are required to provide confirmatory evidence.<\/jats:p><jats:p><jats:bold>Systematic Review Registration:<\/jats:bold><jats:ext-link>https:\/\/www.crd.york.ac.uk\/PROSPERO\/<\/jats:ext-link>, identifier CRD42021277443.<\/jats:p>","DOI":"10.3389\/fphar.2022.946548","type":"journal-article","created":{"date-parts":[[2022,8,31]],"date-time":"2022-08-31T09:20:54Z","timestamp":1661937654000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":13,"title":["Herbal medicine for amyotrophic lateral sclerosis: A systematic review and meta-analysis"],"prefix":"10.3389","volume":"13","author":[{"given":"Yuebo","family":"Song","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuyang","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaorui","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sugimoto","family":"Kazuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weisong","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luda","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,8,31]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/s1474-4422(17)30115-1","article-title":"Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: A randomised, double-blind, placebo-controlled trial","volume":"16","author":"Abe","year":"2017","journal-title":"Lancet Neurol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.pnpbp.2015.07.001","article-title":"Therapeutic potential of cannabis-related drugs","volume":"64","author":"Alexander","year":"2016","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"B3","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/ana.410220308","article-title":"A rating scale for amyotrophic lateral sclerosis: Description and preliminary experience","volume":"22","author":"Appel","year":"1987","journal-title":"Ann. Neurol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3870\/j.issn.1004-0781.2016.z1.021","article-title":"Treatment of amyotrophic lateral sclerosis with Jiawei Sijunzi decoction","volume":"35","author":"Bao","year":"2016","journal-title":"Her. Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1002\/ana.25276","article-title":"Neurofilament light: A candidate biomarker of presymptomatic amyotrophic lateral sclerosis and phenoconversion","volume":"84","author":"Benatar","year":"2018","journal-title":"Ann. Neurol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1056\/NEJM199403033300901","article-title":"A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS\/Riluzole Study Group","volume":"330","author":"Bensimon","year":"1994","journal-title":"N. Engl. J. Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s11910-020-01047-1","article-title":"Sleep and sleep disruption in amyotrophic lateral sclerosis","volume":"20","author":"Boentert","year":"2020","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"B8","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/0022-510x(94)90191-0","article-title":"El escorial World federation of neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on motor neuron diseases\/amyotrophic lateral sclerosis of the World federation of neurology research group on neuromuscular diseases and the El escorial \"clinical limits of amyotrophic lateral sclerosis\" workshop contributors","volume":"124","author":"Brooks","year":"1994","journal-title":"J. Neurol. Sci."},{"key":"B9","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1080\/146608200300079536","article-title":"El escorial revisited: Revised criteria for the diagnosis of amyotrophic lateral sclerosis","volume":"1","author":"Brooks","year":"2000","journal-title":"Amyotroph. Lateral Scler. Other Mot. Neuron Disord."},{"key":"B10","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1056\/NEJMra1603471","article-title":"Amyotrophic lateral sclerosis","volume":"377","author":"Brown","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"2394","DOI":"10.1007\/s12035-018-1236-0","article-title":"Bojungikgi-tang improves muscle and spinal cord function in an amyotrophic lateral sclerosis model","volume":"56","author":"Cai","year":"2019","journal-title":"Mol. Neurobiol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1142\/s0192415x16500233","article-title":"Ginsenoside Re attenuates neuroinflammation in a symptomatic ALS animal model","volume":"44","author":"Cai","year":"2016","journal-title":"Am. J. Chin. Med."},{"key":"B13","first-page":"534","article-title":"Shenmai injection combined with comprehensive therapy for motor neuron disease: A clinical review of 38 cases","volume":"24","author":"Cai","year":"2011","journal-title":"J. Math. Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/s0022-510x(99)00210-5","article-title":"The ALSFRS-R: A revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS study group (phase III)","volume":"169","author":"Cedarbaum","year":"1999","journal-title":"J. Neurol. Sci."},{"key":"B15","doi-asserted-by":"publisher","first-page":"767","DOI":"10.2174\/1871527317666180720162029","article-title":"Amyotrophic lateral sclerosis and oxidative stress: A double-blind therapeutic trial after curcumin supplementation","volume":"17","author":"Chico","year":"2018","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1016\/S1474-4422(14)70222-4","article-title":"Safety and efficacy of ceftriaxone for amyotrophic lateral sclerosis: A multi-stage, randomised, double-blind, placebo-controlled trial","volume":"13","author":"Cudkowicz","year":"2014","journal-title":"Lancet. Neurol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.clinph.2007.09.143","article-title":"Electrodiagnostic criteria for diagnosis of ALS","volume":"119","author":"de Carvalho","year":"2008","journal-title":"Clin. Neurophysiol."},{"key":"B18","article-title":"Assessment of bulbar palsy in amyotrophic lateral sclerosis patients and evaluation of the effect of Jianpiyifei Decoction","volume-title":"Master","author":"Fang","year":"2016"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/S1474-4422(07)70270-3","article-title":"Efficacy of minocycline in patients with amyotrophic lateral sclerosis: A phase III randomised trial","volume":"6","author":"Gordon","year":"2007","journal-title":"Lancet. Neurol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1001\/jamaneurol.2013.6064","article-title":"Phosphorylated tau as a candidate biomarker for amyotrophic lateral sclerosis","volume":"71","author":"Grossman","year":"2014","journal-title":"JAMA Neurol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1080\/146608299300080022","article-title":"Evidence for the validity and reliability of the ALS assessment questionnaire: The ALSAQ-40","volume":"1","author":"Jenkinson","year":"1999","journal-title":"Amyotroph. Lateral Scler. Other Mot. Neuron Disord."},{"key":"B22","doi-asserted-by":"publisher","first-page":"28","DOI":"10.3969\/j.issn.1674-7860.2013.24.012","article-title":"Clinical observation on treating amyotrophic lateral sclerosis by Guilu Erxian glues","volume":"5","author":"Jin","year":"2013","journal-title":"Clin. J. Chin. Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41582-020-00434-z","article-title":"Improving clinical trial outcomes in amyotrophic lateral sclerosis","volume":"17","author":"Kiernan","year":"2021","journal-title":"Nat. Rev. Neurol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1016\/S0140-6736(96)91680-3","article-title":"Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis\/Riluzole Study Group II","volume":"347","author":"Lacomblez","year":"1996","journal-title":"Lancet"},{"key":"B25","article-title":"Chapter 4: Searching for and selecting studies","volume-title":"Cochrane Handbook for systematic reviews of interventions","author":"Lefebvre","year":"2021"},{"key":"B26","first-page":"61","article-title":"Efficacy of Fuyuanshengji Granule on the short period prognosis of the patients with amyotrophic lateral sclerosis","volume":"8","author":"Li","year":"2011","journal-title":"J. Neurology Neurorehabilitation"},{"key":"B27","volume-title":"Effect of Jianpi Yifei Formula on glutamate induced spinal cord neuron injury","author":"Li","year":""},{"key":"B28","first-page":"147","article-title":"Effects of Jianpi Yifei formula combined with massage on neurological function and electromyography in patients with amyotrophic lateral sclerosis","volume":"37","author":"Li","year":"","journal-title":"J. Sichuan Traditional Chin. Med."},{"key":"B29","article-title":"The clinical study of Jiweiling injection in dealing with amyotrophic lateral sclerosis","volume-title":"Master","author":"Ma","year":"2006"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1038\/s41593-021-00936-z","article-title":"Circulating miR-181 is a prognostic biomarker for amyotrophic lateral sclerosis","volume":"24","author":"Magen","year":"2021","journal-title":"Nat. Neurosci."},{"key":"B31","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1212\/wnl.24.8.721","article-title":"The administration of guanidine in amyotrophic lateral sclerosis","volume":"24","author":"Norris","year":"1974","journal-title":"Neurology"},{"key":"B32","doi-asserted-by":"publisher","first-page":"605","DOI":"10.4155\/cli.14.52","article-title":"Outcome measures in amyotrophic lateral sclerosis clinical trials","volume":"4","author":"Paganoni","year":"2014","journal-title":"Clin. Investig. (Lond)"},{"key":"B33","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1056\/NEJMoa1916945","article-title":"Trial of sodium phenylbutyrate-taurursodiol for amyotrophic lateral sclerosis","volume":"383","author":"Paganoni","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"B34","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"B35","volume-title":"Clinical study on treatment of Chong meridian qi adversely ascending type amyotrophic lateral sclerosis by Shenzhe Jiangqi Powder Master","author":"Pan","year":"2015"},{"key":"B36","doi-asserted-by":"publisher","first-page":"613596","DOI":"10.1155\/2013\/613596","article-title":"The use of integrative therapies in patients with amyotrophic lateral sclerosis in shanghai, China","volume":"2013","author":"Pan","year":"","journal-title":"Evid. Based. Complement. Altern. Med."},{"key":"B37","doi-asserted-by":"publisher","first-page":"347525","DOI":"10.1155\/2013\/347525","article-title":"Open randomized clinical trial on JWSJZ Decoction for the treatment of ALS patients","volume":"2013","author":"Pan","year":"","journal-title":"Evid. Based. Complement. Altern. Med."},{"key":"B38","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1097\/wco.0000000000000862","article-title":"Cognitive and behavioural impairment in amyotrophic lateral sclerosis","volume":"33","author":"Pender","year":"2020","journal-title":"Curr. Opin. Neurol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/s1474-4422(18)30406-x","article-title":"Safety and efficacy of nabiximols on spasticity symptoms in patients with motor neuron disease (CANALS): A multicentre, double-blind, randomised, placebo-controlled, phase 2 trial","volume":"18","author":"Riva","year":"2019","journal-title":"Lancet. Neurol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1097\/wco.0000000000000147","article-title":"Disorders of emotional processing in amyotrophic lateral sclerosis","volume":"27","author":"Sedda","year":"2014","journal-title":"Curr. Opin. Neurol."},{"key":"B41","first-page":"497","article-title":"Research Progress on the material basis of pharmacological action of Shenmai Injection","volume":"32","author":"She","year":"2013","journal-title":"Her. Med."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1016\/j.clinph.2020.04.005","article-title":"A proposal for new diagnostic criteria for ALS","volume":"131","author":"Shefner","year":"2020","journal-title":"Clin. Neurophysiol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1212\/01.wnl.0000242887.79115.19","article-title":"The ALSSQOL: Balancing physical and nonphysical factors in assessing quality of life in ALS","volume":"67","author":"Simmons","year":"2006","journal-title":"Neurology"},{"key":"B44","doi-asserted-by":"publisher","first-page":"114774","DOI":"10.1016\/j.jep.2021.114774","article-title":"China amyotrophic lateral sclerosis registry of patients with Traditional Chinese Medicine (CARE-TCM): Rationale and design","volume":"284","author":"Song","year":"2022","journal-title":"J. Ethnopharmacol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: A revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"B46","first-page":"452","article-title":"Treatment of 25 cases of amyotrophic lateral sclerosis with Yiqi Qiangji Decoction","volume":"4","author":"Su","year":"2006","journal-title":"Chin. J. Integr. Med. Cardio-Cerebrovascular Dis."},{"key":"B47","doi-asserted-by":"publisher","first-page":"701886","DOI":"10.3389\/fphar.2021.701886","article-title":"Neuroprotective effects of Shenqi Fuzheng injection in a transgenic SOD1-g93a mouse model of amyotrophic lateral sclerosis","volume":"12","author":"Sugimoto","year":"2021","journal-title":"Front. Pharmacol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"23","DOI":"10.16306\/j.1008-861x.2016.02.006","article-title":"Clinical observation of Huoling Shengji formula in the treatment of amyotrophic lateral sclerosis","volume":"30","author":"Sui","year":"2016","journal-title":"Acad. J. Shanghai Univ. Traditional Chin. Med."},{"key":"B49","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1001\/archneur.1996.00550020045014","article-title":"The Amyotrophic Lateral Sclerosis Functional Rating Scale. Assessment of activities of daily living in patients with amyotrophic lateral sclerosis. The ALS CNTF treatment study (ACTS) phase I-II Study Group","volume":"53","year":"1996","journal-title":"Arch. Neurol."},{"key":"B50","volume-title":"Amyotrophic lateral sclerosis-developing drugs for treatment guidance for industry","year":"2019"},{"key":"B51","volume-title":"Traditional Chinese medicine could make \"Health for one\" true","year":"2021"},{"key":"B52","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1212\/WNL.0000000000012545","article-title":"Innovating clinical trials for amyotrophic lateral sclerosis: Challenging the established order","volume":"97","author":"van Eijk","year":"2021","journal-title":"Neurology"},{"key":"B53","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1136\/jnnp-2019-320998","article-title":"Critical design considerations for time-to-event endpoints in amyotrophic lateral sclerosis clinical trials","volume":"90","author":"van Eijk","year":"2019","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"B54","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1080\/j157v05n03_03","article-title":"The use of herbal supplements and alternative therapies by patients with amyotrophic lateral sclerosis (ALS)","volume":"5","author":"Vardeny","year":"2005","journal-title":"J. Herb. Pharmacother."},{"key":"B55","first-page":"1364","article-title":"Therapeutic effect of strengthening spleen and tonifying lung on amyotrophic lateral sclerosis","volume":"12","author":"Wang","year":"2017","journal-title":"World Chin. Med."},{"key":"B56","first-page":"173","article-title":"Clinical study of the effect of Fuyuan Shengji Granuleon symptoms of the patients with amyotrophic lateral sclerosis","volume":"6","author":"Wang","year":"2009","journal-title":"J. Neurology Neurorehabilitation"},{"key":"B57","volume-title":"Neuroprotective effect of Jiweiling injection on motor neuron disease","author":"Wang","year":"2005"},{"key":"B58","volume-title":"Clinical observation on the treatment of motor neuron disease by nourishing kidney and strengthening spleen (liver-kidney yin deficiency type)","author":"Wang","year":"2017"},{"key":"B59","volume-title":"The clinical study of Jiweiling injection in dealing with amyotrophic lateral sclerosis bulbar paralysis","author":"Wang","year":"2007"},{"key":"B60","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","article-title":"The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection","volume":"30","author":"Ware","year":"1992","journal-title":"Med. Care"},{"key":"B61","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/s1474-4422(18)30089-9","article-title":"Prognosis for patients with amyotrophic lateral sclerosis: Development and validation of a personalised prediction model","volume":"17","author":"Westeneng","year":"2018","journal-title":"Lancet. Neurol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"46","DOI":"10.16306\/j.1008-861x.2011.05.014","article-title":"Clinical observation on the treatment of amyotrophic lateral sclerosis by Tonifying the kidney, strengthening the spleen and soothing the liver","volume":"25","author":"Xv","year":"2011","journal-title":"Acad. J. Shanghai Univ. Traditional Chin. Med."},{"key":"B63","first-page":"72","article-title":"Experimental study and clinical application of Guilu Erxian glue","volume":"42","author":"Xv","year":"2013","journal-title":"Heilongjiang J. Traditional Chin. Med."},{"key":"B64","doi-asserted-by":"publisher","first-page":"49","DOI":"10.3969\/j.issn.1672-0369.2020.08.019","article-title":"Effect of Shenmai Injection on patients with amyotrophic lateral sclerosis","volume":"32","author":"Zhang","year":"2020","journal-title":"Med. J. Chin. People's Health"},{"key":"B65","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1002\/ptr.4960","article-title":"A review of experimental research on herbal compounds in amyotrophic lateral sclerosis","volume":"28","author":"Zhang","year":"2014","journal-title":"Phytother. Res."},{"key":"B66","volume-title":"Neuroprotective therapy in amyotrophic lateral sclerosis model mice","author":"Zhou","year":"2017"},{"key":"B67","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1038\/s41598-018-19923-9","article-title":"Fingerprint analysis of Huolingshengji Formula and its neuroprotective effects in SOD1G93A mouse model of amyotrophic lateral sclerosis","volume":"8","author":"Zhou","year":"2018","journal-title":"Sci. Rep."},{"key":"B68","volume-title":"Exploratory study on the action mechanism of supplementary Sijunzi Decoction in the treatment of amyotrophic lateral sclerosis","author":"Zhu","year":"2016"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.946548\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,31]],"date-time":"2022-08-31T09:21:30Z","timestamp":1661937690000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.946548\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,31]]},"references-count":68,"alternative-id":["10.3389\/fphar.2022.946548"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2022.946548","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,31]]},"article-number":"946548"}}